Navigation Links
New multiple myeloma drug shows promise in treating people with advanced disease
Date:12/10/2012

A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.

A multi-center research team evaluated 113 patients with multiple myeloma who had received at least two prior therapies and had subsequent disease progression to determine safety and efficacy of pomalidomide, a new immunomodulatory drug under review by the FDA. They found significant increases in progression-free survival and overall survival.

"When multiple myeloma no longer responds to two major classes of drugs the average patient survival is only nine months and progression-free survival only five months, representing a significant unmet need for patients with advanced disease," said Sundar Jagannath, MD, Director of the Multiple Myeloma Program and Professor of Medicine at The Tisch Cancer Institute at The Mount Sinai Medical Center and first author on the trial, who presented the trial in an oral abstract session at ASH. "Pomalidomide represents an exciting development for our patients."

Patients were administered four mg/day of pomalidomide plus 40 mg/week of dexamethasone, a steroid used in standard treatment, for 21 days of a 28-day cycle. Progression-free survival was 4.6 months and overall survival was 16.5 months. The scientists also conducted a subanalysis of this group based on age, as treating older people with multiple myeloma is especially difficult. Progression-free survival was 4.7 months in people under 65 and 3.7 months in people over 65, and overall survival was 19.7 months in people under 65 and 11.8 months in people over 65.

"We have made great strides in prolonging the lives of people with multiple myeloma, increasing overall survival from three years to as high as seven years in less than a decade," said Dr. Jagannath. "These results show that pomalidomide in combination with dexamethasone is a promising new option to extend survival even longer, including in older patients."

Pomalidomide was well-tolerated, with patients experiencing side effects common to this drug class, including low white blood cell count, anemia, pneumonia, and low blood platelet count.

The FDA is expected to decide whether to approve pomalidomide in early 2013.

Dr. Jagannath leads one of the largest multiple myeloma research and treatment programs in the world. He and his team, which includes Ajai Chari, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology, seek to explore new treatments for this deadly cancer and extend survival in patients such that it becomes a chronic disease.

The Multiple Myeloma Program at Mount Sinai is one of the leading programs in the country for the diagnosis and treatment of multiple myeloma and sees patients from around the world. The interdisciplinary approach to patient care means that patients are seen by a team of specialists with expertise in the care of patients with multiple myeloma and other hematologic malignancies. The program conducted clinical trials with Lenalidomide and Bortezomib, two novel drugs that are now standard of care. As a result, multiple myeloma patients now have access to highly promising clinical studies and the latest treatment breakthroughs.

Dr. Jagannath receives compensation from Celgene Corporation as a scientific and clinical advisor.


'/>"/>

Contact: Christie Corbett
christie.corbett@mountsinai.org
646-354-9598
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... Long Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... Air & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... to safely and effectively eliminate severe cannabis and tobacco smoke odors without the use ...
(Date:7/21/2017)... Norwalk, Connecticut (PRWEB) , ... July 21, 2017 , ... ... data from HealthCareMandA.com . The number of hospital acquisitions rose to 23 in ... quarter of 2017, and up 15% from the 20 announced deals in the year-ago ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand ... Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... a $5,000 grant from the C. R. Bard Foundation, Inc. to ... Somerset Hills , a service available through the nonprofit home care agency. Using ...
(Date:7/21/2017)... ... ... “Kids aren't born knowing how to regulate their emotions any more than ... St. Louis-based positive education company Generation Mindful. To help with that daunting task, she ... , The kit uses colorful, engaging and educational illustrations and games to teach children ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful carpal tunnel ... syndrome affects more than 8 million people a year. Women suffer ... common methods of treating CTS are painful surgery, the use of ... ... is a clear patch worn on the palm of the hand. ...
(Date:7/11/2017)... July 11, 2017  The global market for liquid ... approximately $394.1 million in 2016.  Although in early stages, ... growth, in particular as a result of the gradual ... the recent introduction of a significant number of new ... testing of tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... 2017  US medical equipment and supply demand is ... Medical Equipment & Supplies: United States ... Continued increases in demand for medical services – driven ... and supported by gains in disposable personal income – ... product introductions will also drive sales as providers and ...
Breaking Medicine Technology: